Last edition
News about "Venatorx Pharmaceuticals"
The oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination is phase 3-ready and being developed as a potential treatment for complicated urinary tract infections (cUTI), including pyelonephritis.
Venatorx Pharmaceuticals | 16/08/2025 | By Darshana | 167
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members